MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

O1918

CAS No. : 536697-79-7

MCE 站：O1918

产品活性：O1918 是 non-CB₁ 受体和 GPR18 的选择性拮抗剂。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Cannabinoid Receptor

In Vivo: Decreases in HR, blood pressure, MBF ａnd RBF by about 20 beats/min, 5-10 mmHg ａnd 0.7 ａnd 0.2 mL/min, respectively, are observed after injection of O1918 (3 µmol/kg). O1918 causes an inhibition of the anandamide-stimulated decreases in MBP, SBP ａnd DBP by 55, 38 ａnd 42% respectively. Similarly, this antagonist reduces the methanandamide-stimulated fall in SBP ａnd DBP by 44 ａnd 32%, respectively, ａnd tends to diminish the decrease in MBP by 28%. O1918 also diminishes the fall in MBF ａnd RBF induced by anandamide by 61 ａnd 67% ａnd that induced by methanandamide by 74 ａnd 49% respectively. Cannabidiol does not affect basal cardiovascular parameters whereas O1918 decreases HR by about 15 beats/min ａnd SBP, DBP ａnd MBP by about 15 mmHg. In pithed rats anandamide (3 µmol/kg) causes only an increase in MBF ａnd RBF. The anandamide-induced long-lasting fall in MBP, SBP ａnd DBP is reduced by cannabidiol by 40-46% ａnd by O-1918 by 55, 64 ａnd 35, respectively.

相关产品：Rimonabant Hydrochloride  |  WIN 55,212-2 Mesylate  |  AM251  |  JD-5037  |  SR144528  |  2-Arachidonoylglycerol  |  6-Iodopravadoline  |  Pregnenolone  |  Anandamide  |  Taranabant  |  β-Caryophyllene  |  Olorinab  |  GW842166X  |  N-Oleoyl glycine  |  Olivetol  |  TM38837  |  EHP-101  |  (±)-Ibipinabant  |  LY2828360  |  Org 27569  |  MDA 19  |  Bay 59-3074  |  CB1 antagonist 2  |  Otenabant  |  Yangonin  |  A-836339  |  AM-6538  |  AZD1940

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。